Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Individuals will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses